北京大学学报(医学版) ›› 2017, Vol. 49 ›› Issue (4): 657-662. doi: 10.3969/j.issn.1671-167X.2017.04.020

• 论著 • 上一篇    下一篇

去势抵抗性前列腺癌进展时间的预测因素分析

纪光杰,黄聪,宋刚△,李学松,宋毅,周利群   

  1. (北京大学第一医院泌尿外科,北京大学泌尿外科研究所,国家泌尿、男性生殖系肿瘤研究中心, 北京100034)
  • 出版日期:2017-08-18 发布日期:2017-08-18
  • 通讯作者: 宋刚 E-mail:sgbmupaper@163.com
  • 基金资助:
    首都临床特色应用研究(Z141107002514089)和吴阶平医学基金(320.6750.12273)资助

Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy

JI Guang-jie, HUANG Cong, SONG Gang△, LI Xue-song, SONG Yi, ZHOU Li-qun   

  1. (Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China)
  • Online:2017-08-18 Published:2017-08-18
  • Contact: SONG Gang E-mail:sgbmupaper@163.com
  • Supported by:
    Supported by the Capital Foundation for Clinical Characteristics and Application Research (Z141107002514089) and Wu Jieping Medical Fund (320.6750.12273)

摘要: 目的:探索前列腺癌经内分泌治疗后进入去势抵抗性前列腺癌(castration-resistant prostate cancer, CRPC)的预测因素,以更好地指导临床和提高患者预后。方法:回顾性分析了2003年1月至2014年12月在北京大学第一医院泌尿外科确诊前列腺癌并且初始治疗为内分泌治疗的患者共185例,收集并整理分析的临床信息包括患者年龄、前列腺癌TNM分期、前列腺癌病理Gleason评分(Gleason score, GS)、前列腺癌危险度、内分泌治疗开始时前列腺特异性抗原(prostate-specific antigen, PSA)水平、经过内分泌治疗后的PSA最低值、PSA下降速率以及降到PSA最低值的时间。应用Kaplan-Meier生存分析和log-rank检验比较不同分组间CRPC进展时间的差异,应用Cox风险比例回归模型来分析评估这些因素对CRPC进展时间的影响。结果:185例患者平均年龄(71.02±8.67)岁,CRPC进展的中位时间为38个月(4~158个月)。单因素分析中,前列腺癌T分期、N分期、前列腺癌危险度、内分泌治疗前是否发生远处转移、PSA下降速率和PSA最低值均与CRPC进展时间显著相关(P值均小于0.01)。在多因素分析中,内分泌治疗前已发生远处转移(HR=6.030,95% CI:3.229~11.263,P=0.001)、较高的PSA最低值(HR=1.185,95% CI:1.080~1.301,P=0.001)、PSA下降速率>11 μg/(L·month)(HR=2.124,95% CI:1.195~3.750,P=0.001)以及到达PSA最低值的时间≤9个月(HR=3.623,95% CI:1.640~4.817,P=0.004)均是CRPC进展时间较短的危险因素。结论:前列腺癌患者经过内分泌治疗后,PSA下降速率越快,进入CRPC时间越短。

关键词: 去势抵抗性前列腺癌, 前列腺特异抗原, 疾病进展, 多因素分析

Abstract: Objective: To explore risk factors including prostate-specific antigen (PSA) kinetics for the prediction of castration-resistant prostate cancer (CRPC), and to build a practical model for predicting the progression to CRPC after androgen deprivation therapy(ADT) so as to facilitate clinicians in decision-making for prostate cancer patients receiving ADT. Methods: A total of 185 patients with prostate cancer who had received ADT as the primary therapy in Department of Urology of Peking University First Hospital from 2003 to 2014 were enrolled retrospectively. All the patients were diagnosed with prostate cancer via prostate biopsy and followed up every four weeks from the initiation of ADT. All the patients received ADT with luteinizing hormone-releasing hormone agonists (LHRH-A) or surgical castration accompanied with an antiandrogen (bicalutamide or flutamide, combined androgen blockade). The clinical information of the patients were collected including age, clinical TNM stage, Gleason score (GS), risk groups of prostate cancer, PSA at the initiation of ADT, PSA nadir after ADT, PSA decline velocity, and the time to PSA nadir. The end point of this study was the diagnosis of CRPC, which was based on the European Association of Urology (EAU) Guideline 2016. Cox proportional hazards regression models were established to analyze and estimate their effects on the time of progression to CRPC. Results: In this study, 185 patients with prostate cancer who had received ADT as the primary therapy were included. The mean age was (71.02±8.67) years. The median time to progression to CRPC in this cohort was 38 months (ranging from 4 to 158 months). On univariate analysis, we found clinical T stage, N stage, the metastasis state before ADT, risk groups of prostate cancer, PSA decline velocity, and PSA nadir were all related to the time to CRPC progression, P<0.01 for all the above variables. And on multivariate analysis, the presence of distant metastasis before ADT (HR=6.030, 95% CI: 3.229-11.263, P=0.001), higher PSA nadir (HR=1.185, 95% CI: 1.080-1.301, P=0.001), higher PSA decline velocity>11 μg/(L·month) (HR=2.124, 95% CI: 1.195-3.750, P=0.001), and time to PSA nadir ≤ 9 months (HR=3.623, 95% CI: 1.640-4.817, P=0.004) were found to be significantly associated with an increased risk of progression to CRPC. Conclusion: Patients with rapid decreasing of PSA in the initial ADT were more likely to progress to CRPC.

Key words: Castration-resistant prostate cancer, Prostate-specific antigen, Disease progression, Multivariate analysis

中图分类号: 

  • R737.25
[1] 范宇, 刘茁, 张莲, 李德润, 何群, 杨新宇, 沈棋, 胡帅, 刘漓波, 山刚志, 李淑清, 孟一森, 王宇, 虞巍, 张骞, 何志嵩, 周利群, 金杰. 中国人惰性前列腺癌临床筛选标准的比较[J]. 北京大学学报(医学版), 2015, 47(4): 586-591.
[2] 王天昱*, 陈晓鹏*, 李学松, 贾元歆, 成俊, 张建华, 蔡林, 张争, 龚侃, 何志嵩, 周利群. 前列腺特异性抗原和Gleason评分对前列腺癌患者核素骨扫描结果的预测价值[J]. 北京大学学报(医学版), 2012, 44(4): 528-534.
[3] 李昕, 张祥华*, 张争, 李淑清, 林健, BPCBPH研究小组▲. 北京多中心社区50岁以上男性年龄与前列腺特异性抗原的关系[J]. 北京大学学报(医学版), 2012, 44(2): 288-290.
[4] GUAN Meng*, 孙烁磊*, XIE Rihua, 黄志平, WEN Shiwu, 关志忱. 16 222名中国男性的年龄相关前列腺特异性抗原参考值范围(附专家点评)[J]. 北京大学学报(医学版), 2011, 43(4): 586-590.
[5] 张崔建, 何志嵩, 周利群. 11年间前列腺癌住院患者临床特征变迁[J]. 北京大学学报(医学版), 2010, 42(4): 404-408.
[6] 刘汀, 王霄英, 王义. 用Cox模型对前列腺癌相关临床检查的多因素生存分析[J]. 北京大学学报(医学版), 2009, 41(2): 184-187.
[7] 许克新, 王晓峰. 良性前列腺增生的前列腺液中低相对分子质量前列腺特异抗原及乳铁蛋白的表达[J]. 北京大学学报(医学版), 2006, 38(6): 648-652.
[8] 徐涛, 陈希, 王晓峰, 侯树坤, 朱积川, 张小东, 黄晓波. 前列腺癌患者外周血中前列腺特异抗原,前列腺特异膜抗原和人腺体激肽释放酶mRNA的表达及临床意义[J]. 北京大学学报(医学版), 2004, 36(2): 164-168.
[9] 李贵忠, 袁亦铭, 张军, 杨新宇, 夏同礼, 郭应禄, 那彦群. 利用前列腺穿刺活检结果预测前列腺癌包膜外侵犯和精囊浸润[J]. 北京大学学报(医学版), 2003, 35(6): 581-585.
[10] 邓动梅, 高学军, 耿秋明, 张侠. 用菌斑成分的多因素分析评价个体的龋易感性[J]. 北京大学学报(医学版), 2002, 34(2): 188-189.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究(英文稿)[J]. 北京大学学报(医学版), 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报(医学版), 2009, 41(2): 125 -128 .
[3] 成刚, 钱振华, 胡军. 艾滋病项目自愿咨询检测的技术效率分析[J]. 北京大学学报(医学版), 2009, 41(2): 135 -140 .
[4] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报(医学版), 2009, 41(2): 158 -161 .
[5] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报(医学版), 2009, 41(2): 217 -220 .
[6] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报(医学版), 2009, 41(1): 52 -55 .
[7] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报(医学版), 2009, 41(1): 109 -111 .
[8] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报(医学版), 2009, 41(3): 297 -301 .
[9] 李宏亮*, 安卫红*, 赵扬玉, 朱曦. 妊娠合并高脂血症性胰腺炎行血液净化治疗1例[J]. 北京大学学报(医学版), 2009, 41(5): 599 -601 .
[10] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报(医学版), 2009, 41(5): 516 -520 .